Compare · PAVM vs TFX
PAVM vs TFX
Side-by-side comparison of PAVmed Inc. (PAVM) and Teleflex Incorporated (TFX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PAVM and TFX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- TFX is the larger of the two at $6.41B, about 703.0x PAVM ($9.1M).
- PAVM has been more active in the news (7 items in the past 4 weeks vs 6 for TFX).
- TFX has more recent analyst coverage (25 ratings vs 0 for PAVM).
- Company
- PAVmed Inc.
- Teleflex Incorporated
- Price
- -
- -
- Market cap
- $9.1M
- $6.41B
- 1M return
- -
- +18.07%
- 1Y return
- -
- +44.92%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 7
- 6
- Recent ratings
- 0
- 25
PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Latest PAVM
- PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
- Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
- Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.
- Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
- PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
- Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
- SEC Form 8-K filed by PAVmed Inc.
Latest TFX
- Amendment: SEC Form SCHEDULE 13G/A filed by Teleflex Incorporated
- Teleflex to Present at the Jefferies Global Healthcare Conference in London
- SEC Form 10-Q filed by Teleflex Incorporated
- Teleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Teleflex Announces Quarterly Dividend
- Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook
- Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
- Teleflex Announces Third Quarter 2026 Earnings Conference Call Information
- Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
- Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology